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Abstract
Background: We evaluated the clinical efficacy and prognosis of muscle-invasive bladder cancer according to the
basal/squamous-like (BASQ) classification system based on immunohistochemical staining [CK5/6(+), CK14(+),
GATA3(−), and FOXA1(−)].
Methods: One hundred patients diagnosed with muscle-invasive bladder cancer (cT2-4 N0-3 M0) were included in
the study. All patients underwent radical cystectomy after transurethral removal of bladder tumor. Immunostaining
was performed for CK5/6, CK14, FOXA1, and GATA3 antibodies on tissue microarray slides, and expression patterns
were quantitatively analyzed using a scanning program.
Results: The median follow-up time was 77.4 (interquartile range: 39–120.9) months. The mean age of the patients
was 65.1 ± 11.2 years. FOXA1 or CK14 expression greater than 1% was respectively positively and negatively
correlated with overall survival (OS; p = 0.011 and p = 0.042, respectively), cancer-specific survival (CSS; p = 0.050 for
both), and recurrence-free survival (RFS; p = 0.018 and p = 0.040, respectively). For CK5/6+ and GATA3- or FOXA1-
expression, 10% CK5/6+ cells were negatively correlated with OS (p = 0.032 and p = 0.039, respectively) and with
RFS in combination with FOXA1- only (p = 0.050).
Conclusions: In this study, CK14 expression was associated with a poor prognosis. The new classification system of
bladder cancer based on molecular characteristics is expected to helpful tool for the establishment of personalized
treatment strategies and associated prediction of therapeutic responses.
Keywords: Basal cell, Immunohistochemistry, Molecular subtype, Neoplasm metastasis, Squamous cell, Urinary
bladder neoplasms
Background
Bladder cancer is the fourth most common cancer in
men, with approximately 60,000 new diagnoses each
year [1], ranking as the eighth leading cause of cancer-
related deaths in the United States, with about 12,000
deaths annually [1]. Specifically, in 2017, there were 79,
030 cases of bladder cancer and 16,870 related deaths in
the United States [1]. Approximately 90–95% of all blad-
der cancer cases are urothelial cell carcinoma, with the
minority consisting of non-urothelial cell carcinoma.
During initial diagnosis, 70–80% of bladder cancers are
diagnosed as non-invasive with the remaining 20–30%
diagnosed as invasive. Most cases of non-invasive blad-
der cancer can be treated with transurethral removal of
the bladder tumor (TURB) alone [2, 3]. However, a high
recurrence rate after TURB has been reported within 1
year (15–70%) and 5 years (7–40%) [2, 3]. Therefore,
continuous additional testing and repeated treatments
are often needed. Indeed, in the United States, bladder
cancer is reportedly one of the tumors for which patients
incur a high costof [2, 3].
Recently, a large-scale, detailed analysis of the molecu-
lar genetic characteristics of bladder cancer was reported
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through The Cancer Genome Atlas (TCGA) [2, 3]. The
TCGA study revealed that bladder cancer can be classi-
fied into several subtypes depending on the molecular
characteristics of the genomes [4–9]: luminal type, basal
type, p53-like tumor, and small cell carcinoma-like
tumor. Among these subtypes, the basal type is associ-
ated with a particularly poor prognosis [4–9]. Moreover,
the basal type and p53-like tumor are highly resistant to
preoperative chemotherapy; thus, identifying the accur-
ate subtype is an essential factor in clinical decision-
making [5]. Basal/squamous-like (BASQ) is a basal type
of bladder cancer with a very poor prognosis and high
rate of resistance to chemotherapy [5]. It is immunohis-
tochemically defined by CK5/6(+), CK14(+), GATA3(−)
and FOXA1(−) expression [5]. However, there is no re-
port on the treatment response and prognosis of patients
with bladder cancer when applying this new classifica-
tion system. Therefore, in the present study, we evalu-
ated the clinical efficacy and prognosis of MIBC




This study was approved by the Institutional Review
Board (IRB No. H-1806-081-951). We used the human
bladder cancer materials stored in the cancer tissue bank
(IRB No. H1307–084-505). We obtained informed con-
sent from all research participants.
Patient populations
A total of 100 patients with muscle-invasive urothelial
carcinoma (cT2-4 N0-3M0) of the urinary bladder were
included in the study. Patient selection was based on the
availability of sufficient material for immunohistochem-
istry. All patients underwent TURB followed by radical
cystectomy between 2000 and 2012 at Seoul National
University Hospital.
Tissue microarray (TMA) construction
Hematoxylin and eosin slides were reviewed for confirm-
ation of the pathologic diagnosis and various pathologic
parameters, including invasion depth and grade. We
constructed TMA blocks from formalin-fixed paraffin-
embedded tissue blocks (Superbiochips Laboratories,
Seoul, Korea). In brief, two representative tumor cores
(2 mm in diameter) were selected from the viable tumor
area. The cancer tissues of patients were examined
microscopically by a skilled pathologist, and the TMA
was prepared after selecting the most representative can-
cer tissues. Immunostaining was performed for CK5/6,
CK14, FOXA1, and GATA3 antibodies on TMA slides
from the 100 patient samples, and the expression pat-
terns were quantitatively analyzed using a scanning
program. Based on the expression patterns, the patients
were divided according to the BASQ classification (CK5/
6, CK14, FOXA1, and GATA3).
The prognostic value of the BASQ classification was
determined based on clinical and pathological informa-
tion such as age, body mass index, sex, American Society
of Anesthesiologists (ASA) physical status, pathologic
TNM stage, carcinoma in situ status, lymphovascular in-
vasion, margin-positive status, lymph node dissection
range, number of removed lymph nodes, number of
positive lymph nodes, and neoadjuvant chemotherapy
enforcement. We also collected various types of onco-
logical data, including the recurrence, mortality, and
cancer-related mortality rates.
Immunohistochemistry (IHC)
IHC staining was performed on 4-μm-thick sections
from TMA blocks using the Benchmark XT autostainer
(Ventana Medical Systems, Tucson, AZ, USA). The sec-
tions were incubated with the following primary anti-
bodies: mouse monoclonal antibodies against CK5/6 (64
min; 1:50; Dako, Glostrup, Denmark), CK14 (32 min; 1:
50; Cell Marque, Rocklin, CA, USA), and GATA3 (32
min; 1:500; clone 156-3C11; Cell Marque), and rabbit
polyclonal antibody against FOXA1 (16 min; 1:700;
ThermoFisher Scientific, Rockford, IL, USA). To inter-
pret the IHC results, the percentage of positively stained
tumor cells was semi-quantitatively evaluated into three
categories; 0, no positive cells; 1+, 1–10% positive cells;
2+, 11–25% positive cells; 3+, > 25% positive cells.
Statistical analysis
Continuous variables are presented as the median value
and interquartile ranges (IQRs) or average value and
standard deviations (SDs). Nominal variables are pre-
sented as the frequency of events (%). The primary end-
point of the study was the overall survival (OS) rate, and
the secondary endpoints were cancer-specific survival
(CSS) and recurrence-free survival (RFS). The Kaplan-
Meier method was used to predict all survival outcomes,
and significance among groups was determined using
log-rank tests. Cox proportional hazards regression ana-
lysis was used for analysis of various oncology outcomes
and predictors. All statistical tests were performed using
IBM SPSS Statistics version 22.0 (IBM, Armonk, NY,
USA) and STATA version 14 (StataCorp LP, College
Station, Texas). A p-value < 0.05 was considered statisti-
cally significant.
Results
Baseline characteristics of the patients
Table 1 shows the basic characteristics of the 100 pa-
tients involved in the study. The median follow-up time
was 77.4 (IQR: 39–120.9) months. The mean age of the
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patients was 65.1 ± 11.2 years, and more than 80% of the
patients were males. Ninety-one patients (91%) had an
ASA physical status below 3. All patients were diagnosed
as having muscle-invasive bladder cancer with T2-4 N0-
3M0; 10% of the patients underwent neoadjuvant
chemotherapy, 35% of the patients underwent radical
cystectomy with standard pelvic lymph node dissection
(PLND), whereas 65% of the patients had extended
PLND. Moreover, 65% of the patients underwent ileal
conduit urinary diversion, and the remaining 35% under-
went neobladder diversion.
Prognostic significance of FOXA1, GATA3, CK14, and CK5/
6 expression
Table 2 shows semi-quantitatively evaluated IHC results.
CK5/6 and CK14 staining showed membranous
expression, and GATA3 and FOXA1 staining was
present in the nucleus (Fig. 1). A frequency of FOXA1
expression greater than 1% was positively correlated with
OS (p = 0.011), CSS (p = 0.050), and RFS (p = 0.018)
(Fig. 2). In addition, a FOXA1 positive frequency greater
than 10% was positively correlated with CSS (p = 0.022),
and a frequency above 25% was positively correlated
with RFS (p = 0.011).
OS, CSS, and RFS all tended to improve in patients
with ≥1% GATA3 expression compared to those with <
1% expression, although the difference was not statisti-
cally significant (Fig. 2). GATA3 expression greater than
10% was positively correlated with RFS (p = 0.032).
A CK14 expression rate greater than 1% was negatively
correlated with OS (p = 0.042), CSS (p = 0.050), and RFS
(p = 0.040) (Fig. 2). Similarly, OS and RFS tended to be
worse in patients with ≥1% CK5/6 expression than in pa-
tients with < 1% CK5/6 expression but not significantly
(Fig. 2). However, CSS was better in patients with < 1%
CK5/6 expression than in those with ≥1% expression
(p = 0.028).
Additional file 1 shows nomogram for predictors of
survival after cystectomy. In multivariable Cox regres-
sion analysis, OS was significantly correlated with the
expression of CK14 (HR: 6.16, 95% CI: 1.28–38.30) and
FOXA1 (HR: 0.08, 95% CI: 0.01–0.59) in the urothelial
carcinoma subtype (Table 3). In CSS, expression of
CK14 (HR: 3.96, 95% CI: 1.13–16.36) and FOXA1 (HR:
0.08, 95% CI: 0.01–0.61) was also significantly correlated.
CK14 was negatively correlated with OS and CSS, and
FOXA1 was positively correlated with OS and CSS
(Table 3). In RFS, only CK14 was negatively correlated
with RFS (HR: 3.19, 95% CI: 1.07–9.55).
A comparison of oncologic outcomes between the < 1%,
1–10%, 11–25, > 25% groups showed that FOXA1 expres-
sion in the 1–10% group was positively correlated with OS
compared to that in less than 1%; OS (p = 0.007), CSS
(p = 0.001), and RFS group (p = 0.025) (Fig. 3). CK14 was
negatively correlated with OS, CSS, and RFS according to
subtype expression level. A comparison of oncologic out-
comes showed that in both the lesser than 1% and be-
tween 11 and 25% groups, CK14 expression between 11
and 25%, was negatively correlated with OS compared to
that in lesser than 1%; OS (p = 0.001), CSS (p = 0.001), and
RFS (p = 0.004) (Fig. 3). A comparison of oncologic out-
comes between the 1 and 10% and between 11 and 25%
groups showed that CK14 expression in the between 11
and 25% group was negatively correlated with OS com-
pared to that in the lesser than 1%; OS (p = 0.002), CSS
(p = 0.001), and RFS group (p = 0.003) (Fig. 3).
Relationship between basal type and prognosis
In the case of CK5/6+ and GATA3- samples, more than 1%
CK5/6 expression and GATA3- expression was significantly
Table 1 Basic patient characteristics
Variable N = 100
Age (mean ± SD) (year) 65.1 ± 11.2






















Removed LN 14.1 ± 12.9
Positive LN 1.0 ± 2.8
Recurrence 31 (31.0%)
Mortality 59 (59.0%)
Cancer related mortality 32 (32.0%)
BMI Body mass index, LVI Lymphovascular invasion, CIS Carcinoma in situ, LND
Lymph node dissection, LN Lymph node;
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negatively correlated with OS (p= 0.032; Fig. 4). In the case
of CK5/6+ and FOXA1- samples, more than 1% CK5/6+ ex-
pression and FOXA1 expression was significantly negatively
correlated with OS and CSS (p= 0.039 and p= 0.050,
respectively; Fig. 4). In the case of CK14+ and GATA3-
samples and CK14+ and FOXA1- samples were not signifi-
cantly correlated with OS, CSS and RFS.
Discussion
Several recent studies have shown that in addition to the
well-known Clinic factors, various antropometric factors
have an effect on the outcome of the bladder cancer
[10–13]. The recurrence rate of bladder cancer is re-
ported to be significantly higher in obese patients than
in normal weight patients [10, 13]. Metabolic features
such as obesity and associated insulin resistance have
also been reported to affect prognosis [13]. High BMI
also helps to predict poor prognosis, such as lymph node
metastasis [10]. Immunological and inflammation
markers such as basophil count, neutrophil and lympho-
cyte count, and C-reactive protein are also helpful in
predicting recurrence after cystectomy or intravesical
Bacillus Calmette-Guérin (BCG) treatment [11, 12].
Table 2 Multivariable Cox regression analysis of overall survival, cancer specific survival, recurrence free survival
Parameter Overall survival Cancer specific survival Recurrence free survival
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
pT stage
T2 reference reference Reference
≥ T3 1.46 (1.15–1.85) 0.002 1.49 (1.17–1.90) 0.001 2.04 (0.38–10.74) 0.400
LVI 0.86 (0.25–2.93) 0.806 2.33 (0.44–12.16) 0.316 2.66 (0.97–7.65) 0.060
CIS 0.90 (0.28–2.89) 0.858 4.15 (1.21–16.03)) 0.028 0.70 (0.43–1.14) 0.160
N stage 0.478 0.096 0.096
N0 reference Reference reference
≥ N1 1.71 (1.46–1.99) < 0.001 1.75 (1.62–1.91) 0.004 2.96 (1.40–6.22) 0.004
CK5/6 3.30 (0.81–14.63) 0.101 2.57 (0.90–8.16) 0.088 3.15 (0.8–12.63) 0.104
CK14 6.16 (1.28–38.30) 0.033 3.96 (1.13–16.36) 0.040 3.19 (1.07–9.55) 0.037
GATA3 0.77 (0.37–1.58) 0.477 0.81 (0.22–2.89) 0.742 0.29 (0.01–5.27) 0.409
FOXA1 0.08 (0.01–0.59) 0.023 0.08 (0.01–0.61) 0.024 0.12 (0.1–1.51) 0.103
HR Hazard ratio, CI Confidence interval, LVI Lymphovascular invasion, CIS Carcinoma in situ, LND Lymph node dissection, LN Lymph node, UC Urothelial carcinoma
Fig. 1 Positive immunohistochemical staining of CK5/6 (a), CK14 (b), GATA3 (c), and FOXA1 (d). CK5/6, CK14 showed membranous staining, and
GATA3, FOXA1 revealed nuclear positivity
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In addition to these various antropometric factors, histo-
logic features have been reported to be helpful in predict-
ing the prognosis of bladder cancer. Recent molecular
studies have provided new insight into the factors contrib-
uting to bladder cancer development and progression.
TMAs have been used to analyze genome expression, and
immunohistochemical expression patterns are used to
classify unique molecular types of bladder cancer. The
gene mutations identified to date include genes related to
chromatin regulation, cell cycle regulation, and kinase sig-
naling pathways. In particular, molecular insight has been
gained with respect to the cell and molecular biology of
the urothelium, with 32 gene mutations significantly and
repeatedly observed in urothelial cell carcinoma, including
genes related to cell cycle regulation, chromatin regula-
tion, and kinase signaling pathways [5]. In particular,
tumor protein 53 (TP53), fibroblast growth factor
receptor-3 (FGFR3) mutations, and genes involved in the
phosphatidylinositol-3-OH kinase (Pl3K)/protein kinase B
(Akt)/mammalian target of rapamycin (mTOR) pathway
were found to be associated with the prognosis of bladder
cancer [5].
Besides the specific mutations and pathways, the
discovery of molecular subtypes of urothelial cell carcinoma
represents another important advance obtained through
molecular studies. Several studies on genome expression
profiles have reported that bladder cancer can be
categorized into two intrinsic molecular types: luminal and
basal, which are similar to those in breast cancer [5, 14, 15].
The molecular subtype of urothelial carcinoma is related to
cell differentiation [16]. Basal type and luminal type are dis-
tinguished by keratin markers. The basal type has keratins
representing the basal/stem-cell compartment, and the lu-
minal type has keratins representing the umbrella cell layer
Fig. 2 Oncologic outcomes according to subtypes of urothelial carcinoma. a overall survival, b cancer specific survival, c recurrence free survival
Table 3 Immunohistochemistry results
CK14 CK5/6 GATA3 FOXA1
< 1% 60 (60.0%) 24 (24.0%) 8 (8.0%) 15 (15.0%)
1~10% 12 (12.0%) 35 (35.0%) 11 (11.0%) 15 (15.0%)
11~25% 15 (15.0%) 16 (16.0%) 14 (14.0%) 20 (20.0%)
> 25% 13 (13.0%) 25 (25.0%) 67 (67.0%) 50 (50.0%)
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[6, 15]. Basal type keratins are associated with the transcrip-
tion factor ΔNP63, which is related to a poor prognosis of
muscle-invasive bladder cancer [15, 16].
Lindgren et al. [8] first classified samples from 144
patients with urothelial cell carcinoma according to gene
expression patterns. They divided the urobasal group
into two subgroups: urobasal A and B, according to their
molecular characteristics. Urobasal A was mostly a non-
muscle invasive bladder cancer; however, patients with
urobasal B showed a progressive phenotype with in-
creased cell cycle activity and basal cell-related keratin
expression [7].
The MD Anderson cohort was classified into basal
and luminal types, which included 98 patients with inva-
sive bladder cancers and 34 patients with superficial
bladder cancers. The luminal type showed strong ex-
pression of markers such as CD24, FOXA1, GATA3,
CK20, and XBP1, whereas the basal type was character-
ized by high-molecular-weight keratins (CK5 and CK14)
and strong expression of CDH3 and CD44 [5, 17].
Thus, the molecular characteristics of urothelial car-
cinoma can be used to predict the therapeutic effect and
prognosis of the patient. McConkey et al.[18] reported
that these molecular characteristics could predict the
benefits of treatment such as chemotherapy or target
agent therapy. Specifically, basal subtypes have been
shown to be beneficial in neoadjuvant settings.[18].
Our present study also showed a tendency for a better
prognosis in cancers with FOXA1 or GATA3 expression.
Conversely, some of the CK14 and CK5/6-positive cases
showed a tendency to be correlated with a poor progno-
sis. CK 14 negatively correlated with OS, CSS, and RFS,
and FOXA1 positively correlated with OS and CSS. The
expression of CK14 and FOXA1 subtypes seemed to be
correlated with oncologic outcomes compared to those
of CK56 and GATA3. Indeed, CK14 and FOXA1 expres-
sion may be a sensitive criterion for further differentiat-
ing urothelial carcinoma. However, our study was
limited to 100 subjects and the results may be due to
these limited subjects.
Fig. 3 Comparison of oncologic outcome according to expression level of subtypes of urothelial carcinoma. a Overall survival, b Cancer specific
survival, c Recurrence free survival
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The difference in survival outcomes according to the de-
gree of subtype expression was not significantly correlated
with oncologic outcomes. However, CK14 and FOXA1 ex-
pression was correlated with oncologic outcomes at some
yields. FOXA1 expression in the between 1 and 10% group
was positively correlated with OS compared to that in the
lesser than 1% group, OS (p = 0.007), CSS (p = 0.001), and
RFS (p = 0.025) (Fig. 3).
CK14 also showed differences in oncologic outcome of
OS and CSS according to subtype expression levels. There
was a difference in the oncologic outcomes between the
less than 1%, between 11 and 25%, and more than 25%
groups. CK14 is negatively correlated with OS, CSS, and
RFS according to subtype expression level (Fig. 3).
Even if FOXA1 is statistically significant in multivariate
Cox regression analysis, the odd ratio is 0.08 and its im-
pact is unclear. However, CK14 expression was associated
with oncologic outcome of OS and CSS. (Table 3).
In the case of basal type cancers (CK14+, CK5/6+,
FOXA1-, GATA3-), CK5/6+ and GATA3- were signifi-
cantly correlated with a poor OS when the CK5/6+ ex-
pression rate was > 10%. CK5/6+ and FOXA1- were also
significantly correlated with a poor OS and RFS when
the CK5/6+ expression rate was > 10 and > 25%. When
we defined the basal type according to the new consen-
sus, we found a significant correlation with poor OS,
and a tendency toward an association with RFS. This
somewhat unclear correlation is likely due to the insuffi-
cient number of specimens analyzed in our study. How-
ever, this finding suggests a clear relationship between
the basal type and a poor prognosis.
This study has some limitations. This study had a
retrospective design, and the sample size was relatively
small. Therefore, more extensive and prospective studies
are needed to verify the observed associations. And we
did not consider the number of TURBs or intravesical
treatments that could affect the outcome. Nevertheless,
it is meaningful that this study applied the newly estab-
lished BASQ classification to the evaluation of clinical
specimens from patients diagnosed with bladder cancer
and related the BASQ classification to prognosis. We
could also confirm that the basal and luminal types in
the BASQ classification are closely related to patient
prognosis.
Conclusions
In this study, CK14 expression was associated with a poor
prognosis. The new classification system of bladder cancer
based on molecular characteristics is expected to helpful
tool for the establishment of personalized treatment strat-
egies and associated prediction of therapeutic responses.
Additional file
Additional file 1: Figure S1. Nomogram for prediction of survival after
cystectomy. (TIF 21 kb)
Abbreviations
Akt: protein kinase B; ASA: American society of anesthesiologists;
BASQ: basal/squamous-like; FGFR3: fibroblast growth factor receptor-3;
IHC: Immunohistochemistry; mTOR: mammalian target of rapamycin;
Pl3K: phosphatidylinositol-3-OH kinase; PLND: pelvic lymph node dissection;
TCGA: the cancer genome atlas; TMA: tissue microarray; TP53: tumor protein
53; TURB: transurethral removal of the bladder tumor
Author’s contributions
Conception and design JK, KM, HY, CJ, CK, HK acquisition of data HY, CJ, KM,
JK analysis and interpretation of data HY, KM, JK drafting of the manuscript
HY critical revision of the manuscript for important intellectual content HY,
KM, CJ, CK, HK, KM, statistical analysis HY, KM, JK obtaining funding JK
Fig. 4 Oncologic outcomes according to ck5/6(+) and gata3(−) and ck5/6(+) and foxa1(−) in immunochemical staining. a Overall survival, b
Cancer specific survival, c Recurrence free survival
Yuk et al. BMC Cancer          (2019) 19:897 Page 7 of 8
administrative, technical, or material support CJ, CK, HK supervision KM, JK.
All authors read and approved the final manuscript.
Funding
This study was supported by the National Research Foundation of Korea
(NRF) grant funded by the Korea government (MSIP) (Grant number:
2016R1A2B4011623). No funders had any role in study concept and design,
experiments, analysis of data, writing manuscript, or the decision for
publication.
This study was supported by the 2015 Korean Urologic Oncology Society
Grant.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
This study was approved by the Institutional Review Board of Seoul National
University Hospital (IRB No. H-1806-081-951). We used the human bladder
cancer materials stored in the cancer tissue bank of Seoul National University
Hospital (IRB No. H1307–084-505). We obtained informed written consent




The authors declare that they have no competing interests.
Author details
1Department of Urology, Inje University College of Medicine, Inje University
Sanggye Paik Hospital, Seoul, Korea. 2Department of Urology, Seoul National
Univervity College of Medicine, Seoul National University Hospital, Seoul,
Korea. 3Department of Pathology, Seoul National Univervity College of
Medicine, Seoul National University Hospital, Seoul, Korea.
Received: 7 May 2019 Accepted: 15 August 2019
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;
67(1):7–30. https://doi.org/10.3322/caac.21387.
2. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E,
et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of
the bladder: update 2013. Eur Urol. 2013;64(4):639–53. https://doi.org/1
0.1016/j.eururo.2013.06.003.
3. Burger M, Oosterlinck W, Konety B, Chang S, Gudjonsson S, Pruthi R, et al.
ICUD-EAU international consultation on bladder cancer 2012: non-muscle-
invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63(1):36–44.
https://doi.org/10.1016/j.eururo.2012.08.061.
4. Cancer Genome Atlas Research N. Comprehensive molecular
characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):
315–22. https://doi.org/10.1038/nature12965.
5. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al.
Identification of distinct basal and luminal subtypes of muscle-invasive
bladder cancer with different sensitivities to frontline chemotherapy. Cancer
Cell. 2014;25(2):152–65. https://doi.org/10.1016/j.ccr.2014.01.009.
6. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, et al.
Multiplatform analysis of 12 cancer types reveals molecular classification
within and across tissues of origin. Cell. 2014;158(4):929–44. https://doi.org/1
0.1016/j.cell.2014.06.049.
7. Lindgren D, Frigyesi A, Gudjonsson S, Sjodahl G, Hallden C, Chebil G, et al.
Combined gene expression and genomic profiling define two intrinsic
molecular subtypes of urothelial carcinoma and gene signatures for
molecular grading and outcome. Cancer Res. 2010;70(9):3463–72. https://
doi.org/10.1158/0008-5472.CAN-09-4213.
8. Rebouissou S, Bernard-Pierrot I, de Reynies A, Lepage ML, Krucker C,
Chapeaublanc E, et al. EGFR as a potential therapeutic target for a
subset of muscle-invasive bladder cancers presenting a basal-like
phenotype. Sci Transl Med. 2014;6(244):244ra291. https://doi.org/10.1126/
scitranslmed.3008970.
9. Volkmer JP, Sahoo D, Chin RK, Ho PL, Tang C, Kurtova AV, et al. Three
differentiation states risk-stratify bladder cancer into distinct subtypes.
Proc Natl Acad Sci U S A. 2012;109(6):2078–83. https://doi.org/10.1073/
pnas.1120605109.
10. Cantiello F, Cicione A, Autorino R, Salonia A, Briganti A, Ferro M, et al.
Visceral obesity predicts adverse pathological features in urothelial
bladder cancer patients undergoing radical cystectomy: a retrospective
cohort study. World J Urol. 2014;32(2):559–64. https://doi.org/10.1007/
s00345-013-1147-7.
11. Ferro M, De Cobelli O, Buonerba C, Di Lorenzo G, Capece M, Bruzzese D, et
al. Modified Glasgow prognostic score is associated with risk of recurrence
in bladder Cancer patients after radical cystectomy: a multicenter
experience. Medicine (Baltimore). 2015;94(42):e1861. https://doi.org/10.1097/
MD.0000000000001861.
12. Ferro M, Di Lorenzo G, Vartolomei MD, Bruzzese D, Cantiello F, Lucarelli G,
et al. Absolute basophil count is associated with time to recurrence in
patients with high-grade T1 bladder cancer receiving bacillus Calmette-
Guerin after transurethral resection of the bladder tumor. World J Urol.
2019. https://doi.org/10.1007/s00345-019-02754-2.
13. Ferro M, Vartolomei MD, Russo GI, Cantiello F, Farhan ARA, Terracciano D, et
al. An increased body mass index is associated with a worse prognosis in
patients administered BCG immunotherapy for T1 bladder cancer. World J
Urol. 2019;37(3):507–14. https://doi.org/10.1007/s00345-018-2397-1.
14. Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, et al.
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of
breast cancer biology. Proc Natl Acad Sci U S A. 2014;111(8):3110–5. https://
doi.org/10.1073/pnas.1318376111.
15. Kim J, Akbani R, Creighton CJ, Lerner SP, Weinstein JN, Getz G, et al. Invasive
bladder cancer: genomic insights and therapeutic promise. Clin Cancer Res.
2015;21(20):4514–24. https://doi.org/10.1158/1078-0432.CCR-14-1215.
16. Ho PL, Kurtova A, Chan KS. Normal and neoplastic urothelial stem cells:
getting to the root of the problem. Nat Rev Urol. 2012;9(10):583–94. https://
doi.org/10.1038/nrurol.2012.142.
17. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al.
Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–
52. https://doi.org/10.1038/35021093.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Yuk et al. BMC Cancer          (2019) 19:897 Page 8 of 8
